Investment Research and Business Due Diligence
Monday, April 15, 2013
Epadel T - Taisho launches Japan's first switch OTC drug for lifestyle diseases
Taisho Pharmaceutical Co., Ltd. has announced that it will launch “Epadel T” , a treatment for improving abnormal triglyceride levels. The drug marketing approval for “Epadel T” has been obtained by Mochida Pharmaceutical Co., Ltd.
Epadel T” was developed by converting the ethical drugs Epadel” into an OTC drug, making it Japan’s first switch-OTC drug for lifestyle-related diseases. “Epadel” is a prescription pharmaceutical treatment for hyperlipidemia and arteriosclerosis obliterans that is manufactured and sold by Mochida Pharmaceutical. The active ingredient is EPA-E (Generic name: ethyl icosapentate). “Epadel T” contains 600 mg of EPA-E per packet, and is indicated for “the treatment of triglyceride levels that are in the borderline region, identified through health check-ups and other means.”
In the run-up to the nationwide launch of “Epadel T,” Taisho Pharmaceutical will conduct a survey on proper use in accordance with the instructions of the Ministry of Health, Labour and Welfare.
This survey is designed to confirm whether or not pharmacists are able to determine customers suitable for taking this drug, and to provide proper guidance on drug administration, recommendations to see a doctor, and other services. During the survey period, “Epadel T” will be sold only at drugstores implementing the survey. Furthermore, Taisho Pharmaceutical will provide customers with the information they need to properly take “Epadel T.”
Mochida Pharmaceutical will continue to market the prescription pharmaceuticals “Epadel” for medical use.
Enter your email address:
Share to Twitter
Share to Facebook
Share to Pinterest
Post Comments (Atom)